Hangzhou Bio-Sincerity Pharma-TechLtd Past Earnings Performance
Past criteria checks 1/6
Hangzhou Bio-Sincerity Pharma-TechLtd has been growing earnings at an average annual rate of 34.7%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 39.9% per year. Hangzhou Bio-Sincerity Pharma-TechLtd's return on equity is 7.7%, and it has net margins of 20.7%.
Key information
34.7%
Earnings growth rate
28.0%
EPS growth rate
Life Sciences Industry Growth
26.8%
Revenue growth rate
39.9%
Return on equity
7.7%
Net Margin
20.7%
Last Earnings Update
30 Sep 2024
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Hangzhou Bio-Sincerity Pharma-TechLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
XSEC:301096 Revenue, expenses and earnings (CNY Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
30 Sep 24
1,025
212
120
321
30 Jun 24
1,119
287
172
298
31 Mar 24
1,072
287
156
260
31 Dec 23
1,017
272
159
240
30 Sep 23
900
250
155
203
30 Jun 23
786
229
153
184
31 Mar 23
673
210
131
164
01 Jan 23
607
194
113
163
30 Sep 22
573
192
93
149
30 Jun 22
479
155
75
120
31 Mar 22
425
126
70
110
31 Dec 21
374
111
62
78
30 Sep 21
304
101
51
51
30 Jun 21
267
85
48
44
31 Mar 21
211
55
46
36
31 Dec 20
207
57
50
32
31 Dec 19
156
44
35
15
31 Dec 18
82
11
23
12
31 Dec 17
26
-7
10
8
30 Jun 17
30
8
11
0
31 Mar 17
27
5
11
0
31 Dec 16
24
3
12
0
30 Sep 16
21
1
12
0
30 Jun 16
16
-1
11
0
31 Mar 16
16
2
8
0
01 Jan 16
16
5
4
0
31 Dec 14
6
-2
4
0
Quality Earnings: 301096 has a high level of non-cash earnings.
Growing Profit Margin: 301096's current net profit margins (20.7%) are lower than last year (27.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301096's earnings have grown significantly by 34.7% per year over the past 5 years.
Accelerating Growth: 301096's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301096 had negative earnings growth (-15.3%) over the past year, making it difficult to compare to the Life Sciences industry average (-14.4%).
Return on Equity
High ROE: 301096's Return on Equity (7.7%) is considered low.